Boston Scientific says will move into resorbable scaffold market with caution
This article was originally published in Clinica
Executive Summary
Boston Scientific last week launched its first trial for a fully bioresorbable coronary scaffold, but executives have suggested that the firm is treading carefully to see if it offers sufficient advantage over Boston's successful Synergy stent, which has a bioresorbable polymer coating, to warrant long-term investment.